FDAsafety guidance54% confidence
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (breast cancer) as AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Breast Cancer
- Sub-indication
- Breast Cancer
Related signal: Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy